Having some free time following the $10.8 billion buyout of Prometheus Biosciences made Mark McKenna realize he had some “unfinished business.”
Merck closed its $10.8 billion acquisition of Prometheus Biosciences, setting the stage for the drugmaker’s pursuit of an immunology blockbuster.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
After releasing positive data for a bowel disease candidate in December, Prometheus Biosciences headed into the J.P. Morgan Healthcare conference in January as the talk of San Francisco.
In the week after this year’s JP Morgan Healthcare Conference, Prometheus Biosciences CEO Mark McKenna got a phone call that would change the biotech’s future.
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)